Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery.

Li QR, Wang ZM, Wewer Albrechtsen NJ, Wang DD, Su ZD, Gao XF, Wu QQ, Zhang HP, Zhu L, Li RX, Jacobsen S, Jørgensen NB, Dirksen C, Bojsen-Møller KN, Petersen JS, Madsbad S, Clausen TR, Diderichsen B, Chen LN, Holst JJ, Zeng R, Wu JR.

EBioMedicine. 2018 Feb;28:234-240. doi: 10.1016/j.ebiom.2018.01.018. Epub 2018 Feb 2.

2.

First trimester pregnancy ultrasound findings as a function of method of conception in an infertile population.

von Versen-Höynck F, Petersen JS, Chi YY, Liu J, Baker VL.

J Assist Reprod Genet. 2018 May;35(5):863-870. doi: 10.1007/s10815-018-1120-x. Epub 2018 Jan 29.

PMID:
29380277
3.

The influence of feeding crimped kernel maize silage on broiler production, nutrient digestibility and meat quality.

Ranjitkar S, Karlsson AH, Petersen MA, Bredie WL, Petersen JS, Engberg RM.

Br Poult Sci. 2016;57(1):93-104. doi: 10.1080/00071668.2015.1115468.

PMID:
26551864
4.

Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes.

Max Andersen ML, Hougaard P, Pörksen S, Nielsen LB, Fredheim S, Svensson J, Thomsen J, Vikre-Jørgensen J, Hertel T, Petersen JS, Hansen L, Mortensen HB.

Pediatr Diabetes. 2014 Nov;15(7):469-76. doi: 10.1111/pedi.12208.

PMID:
25287319
5.

Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies.

Haselmayer P, Camps M, Muzerelle M, El Bawab S, Waltzinger C, Bruns L, Abla N, Polokoff MA, Jond-Necand C, Gaudet M, Benoit A, Bertschy Meier D, Martin C, Gretener D, Lombardi MS, Grenningloh R, Ladel C, Petersen JS, Gaillard P, Ji H.

Front Immunol. 2014 May 22;5:233. doi: 10.3389/fimmu.2014.00233. eCollection 2014.

6.

Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr.

Max Andersen ML, Nielsen LB, Svensson J, Pörksen S, Hougaard P, Beam C, Greenbaum C, Becker D, Petersen JS, Hansen L, Mortensen HB.

Pediatr Diabetes. 2014 Aug;15(5):345-54. doi: 10.1111/pedi.12098. Epub 2013 Nov 25.

PMID:
24731251
7.

2-Colour photolithography.

Fourkas JT, Petersen JS.

Phys Chem Chem Phys. 2014 May 21;16(19):8731-50. doi: 10.1039/c3cp52957f.

PMID:
24705478
8.

Complex multi-block analysis identifies new immunologic and genetic disease progression patterns associated with the residual β-cell function 1 year after diagnosis of type 1 diabetes.

Andersen ML, Rasmussen MA, Pörksen S, Svensson J, Vikre-Jørgensen J, Thomsen J, Hertel NT, Johannesen J, Pociot F, Petersen JS, Hansen L, Mortensen HB, Nielsen LB.

PLoS One. 2013 Jun 5;8(6):e64632. doi: 10.1371/journal.pone.0064632. Print 2013.

9.

Murine extracellular superoxide dismutase is converted into the inactive fold by the Ser195Cys mutation.

Scavenius C, Petersen JS, Thomsen LR, Poulsen ET, Valnickova-Hansen Z, Bowler RP, Oury TD, Petersen SV, Enghild JJ.

Biochemistry. 2013 May 14;52(19):3369-75. doi: 10.1021/bi400171b. Epub 2013 May 1.

PMID:
23594119
10.

Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study.

Hove KD, Brøns C, Færch K, Lund SS, Petersen JS, Karlsen AE, Rossing P, Rehfeld JF, Vaag A.

Diabetologia. 2013 Jan;56(1):22-30. doi: 10.1007/s00125-012-2714-y. Epub 2012 Sep 26.

PMID:
23011351
11.

Proinsulin, GLP-1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes.

Kaas A, Andersen ML, Fredheim S, Hougaard P, Buschard K, Petersen JS, de Beaufort C, Robertson KJ, Hansen L, Mortensen HB, Nielsen LB; Hvidoere Study Group on childhood diabetes.

Pediatr Diabetes. 2012 Feb;13(1):51-8. doi: 10.1111/j.1399-5448.2011.00812.x. Epub 2011 Nov 27.

PMID:
22118630
12.

Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts.

Axelsen LN, Keung W, Pedersen HD, Meier E, Riber D, Kjølbye AL, Petersen JS, Proctor SD, Holstein-Rathlou NH, Lopaschuk GD.

Br J Pharmacol. 2012 Apr;165(8):2736-48. doi: 10.1111/j.1476-5381.2011.01714.x.

13.

Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21.

Possenti R, Muccioli G, Petrocchi P, Cero C, Cabassi A, Vulchanova L, Riedl MS, Manieri M, Frontini A, Giordano A, Cinti S, Govoni P, Graiani G, Quaini F, Ghè C, Bresciani E, Bulgarelli I, Torsello A, Locatelli V, Sanghez V, Larsen BD, Petersen JS, Palanza P, Parmigiani S, Moles A, Levi A, Bartolomucci A.

Biochem J. 2012 Jan 1;441(1):511-22. doi: 10.1042/BJ20111165.

PMID:
21880012
14.

ZP2307, a novel, cyclic PTH(1-17) analog that augments bone mass in ovariectomized rats.

Neerup TS, Stahlhut M, Petersen JS, Daugaard JR, Jensen JE, Peng Z, Morko J, Thorkildsen C.

Bone. 2011 Jun 1;48(6):1319-27. doi: 10.1016/j.bone.2011.02.019. Epub 2011 Mar 1.

PMID:
21376152
15.

Advances in pemphigus research, signaling, and acantholysis.

Bektas M, Runager K, Petersen JS, Rubenstein DS.

G Ital Dermatol Venereol. 2010 Oct;145(5):675-87.

PMID:
20930701
16.

Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients - a retrospective analysis.

Hove KD, Færch K, Bödvarsdóttir TB, Karlsen AE, Petersen JS, Vaag A.

Diabetes Res Clin Pract. 2010 Dec;90(3):e72-4. doi: 10.1016/j.diabres.2010.09.007.

PMID:
20888658
17.

The concentration of extracellular superoxide dismutase in plasma is maintained by LRP-mediated endocytosis.

Petersen SV, Thøgersen IB, Valnickova Z, Nielsen MS, Petersen JS, Poulsen ET, Jacobsen C, Oury TD, Moestrup SK, Crapo JD, Nielsen NC, Kristensen T, Enghild JJ.

Free Radic Biol Med. 2010 Sep 1;49(5):894-9. doi: 10.1016/j.freeradbiomed.2010.06.019. Epub 2010 Jun 27.

PMID:
20600835
18.

Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes.

Bödvarsdóttir TB, Hove KD, Gotfredsen CF, Pridal L, Vaag A, Karlsen AE, Petersen JS.

Diabetologia. 2010 Oct;53(10):2220-3. doi: 10.1007/s00125-010-1825-6. Epub 2010 Jun 30.

19.

Cardiac and metabolic changes in long-term high fructose-fat fed rats with severe obesity and extensive intramyocardial lipid accumulation.

Axelsen LN, Lademann JB, Petersen JS, Holstein-Rathlou NH, Ploug T, Prats C, Pedersen HD, Kjølbye AL.

Am J Physiol Regul Integr Comp Physiol. 2010 Jun;298(6):R1560-70. doi: 10.1152/ajpregu.00392.2009. Epub 2010 Mar 31.

20.

Metabolic and cardiac changes in high cholesterol-fructose-fed rats.

Axelsen LN, Pedersen HD, Petersen JS, Holstein-Rathlou NH, Kjølbye AL.

J Pharmacol Toxicol Methods. 2010 May-Jun;61(3):292-6. doi: 10.1016/j.vascn.2010.02.009. Epub 2010 Feb 19.

PMID:
20172035
21.

Amylin(1-8) is devoid of anabolic activity in bone.

Ellegaard M, Thorkildsen C, Petersen S, Petersen JS, Jørgensen NR, Just R, Schwarz P, Ramirez MT, Stahlhut M.

Calcif Tissue Int. 2010 Mar;86(3):249-60. doi: 10.1007/s00223-010-9338-3. Epub 2010 Feb 3.

PMID:
20127324
22.

GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

Hennan JK, Swillo RE, Morgan GA, Rossman EI, Kantrowitz J, Butera J, Petersen JS, Gardell SJ, Vlasuk GP.

J Cardiovasc Pharmacol Ther. 2009 Sep;14(3):207-14. doi: 10.1177/1074248409340779.

PMID:
19721133
23.

The anti-arrhythmic peptide AAP10 remodels Cx43 and Cx40 expression and function.

Easton JA, Petersen JS, Martin PE.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Jul;380(1):11-24. doi: 10.1007/s00210-009-0411-2. Epub 2009 Mar 27.

PMID:
19326099
24.

[Future breakthroughs in medical treatment of age-related conditions].

Vaag A, Petersen JS.

Ugeskr Laeger. 2009 Mar 2;171(10):794-6. Danish.

PMID:
19265603
25.

The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.

Rossman EI, Liu K, Morgan GA, Swillo RE, Krueger JA, Gardell SJ, Butera J, Gruver M, Kantrowitz J, Feldman HS, Petersen JS, Haugan K, Hennan JK.

J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33. doi: 10.1124/jpet.108.150102. Epub 2009 Feb 27.

PMID:
19252062
26.

Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation.

Butera JA, Larsen BD, Hennan JK, Kerns E, Di L, Alimardanov A, Swillo RE, Morgan GA, Liu K, Wang Q, Rossman EI, Unwalla R, McDonald L, Huselton C, Petersen JS.

J Med Chem. 2009 Feb 26;52(4):908-11. doi: 10.1021/jm801558d.

PMID:
19175320
27.

Nociceptin/orphanin FQ peptide receptor agonist Ac-RYYRWKKKKKKK-NH2 (ZP120) induces antinatriuresis in rats by stimulation of amiloride-sensitive sodium reabsorption.

van Deurs US, Hadrup N, Petersen JS, Christensen S, Jonassen TE.

J Pharmacol Exp Ther. 2009 Feb;328(2):533-9. doi: 10.1124/jpet.108.144774. Epub 2008 Nov 21.

PMID:
19028991
28.

Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120.

Fischetti C, Rizzi A, Gavioli EC, Marzola G, Trapella C, Guerrini R, Petersen JS, Calo G.

Peptides. 2009 Feb;30(2):248-55. doi: 10.1016/j.peptides.2008.10.001. Epub 2008 Oct 17.

PMID:
18992780
29.

The future of diabetes treatment.

Petersen JS.

Ann Endocrinol (Paris). 2008 Apr;69(2):166-7. doi: 10.1016/j.ando.2008.02.023. Epub 2008 Apr 28. Review. No abstract available.

PMID:
18440491
30.

Enhancement of ventricular gap-junction coupling by rotigaptide.

Lin X, Zemlin C, Hennan JK, Petersen JS, Veenstra RD.

Cardiovasc Res. 2008 Aug 1;79(3):416-26. doi: 10.1093/cvr/cvn100. Epub 2008 Apr 22.

31.

The folding of human active and inactive extracellular superoxide dismutases is an intracellular event.

Petersen SV, Kristensen T, Petersen JS, Ramsgaard L, Oury TD, Crapo JD, Nielsen NC, Enghild JJ.

J Biol Chem. 2008 May 30;283(22):15031-6. doi: 10.1074/jbc.M801548200. Epub 2008 Apr 2.

32.

ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries.

Simonsen U, Laursen BE, Petersen JS.

Br J Pharmacol. 2008 Mar;153(6):1185-94. doi: 10.1038/sj.bjp.0707688. Epub 2008 Jan 14.

33.

Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.

Kjølbye AL, Haugan K, Hennan JK, Petersen JS.

Basic Clin Pharmacol Toxicol. 2007 Oct;101(4):215-30. Review.

34.

Differential down-regulation of aquaporin-2 in rat kidney zones by peripheral nociceptin/orphanin FQ receptor agonism and vasopressin type-2 receptor antagonism.

Hadrup N, Petersen JS, Windfeld S, Risom L, Andersen CB, Nielsen S, Christensen S, Jonassen TE.

J Pharmacol Exp Ther. 2007 Nov;323(2):516-24. Epub 2007 Aug 10.

PMID:
17693587
35.

Increasing gap junctional coupling: a tool for dissecting the role of gap junctions.

Axelsen LN, Haugan K, Stahlhut M, Kjølbye AL, Hennan JK, Holstein-Rathlou NH, Petersen JS, Nielsen MS.

J Membr Biol. 2007 Mar;216(1):23-35. Epub 2007 Jun 14. Review.

PMID:
17568971
36.

Small-molecule agonists for the glucagon-like peptide 1 receptor.

Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, Holst JJ, Jeppesen CB, Johnson MD, de Jong JC, Jorgensen AS, Kercher T, Kostrowicki J, Madsen P, Olesen PH, Petersen JS, Poulsen F, Sidelmann UG, Sturis J, Truesdale L, May J, Lau J.

Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):937-42. Epub 2007 Jan 9.

37.

Antigen-based prediction and prevention of type 1 diabetes.

Petersen JS.

Dan Med Bull. 2006 Nov;53(4):418-37. Review. No abstract available.

PMID:
17150147
38.

The antiarrhythmic peptide rotigaptide (ZP123) increases connexin 43 protein expression in neonatal rat ventricular cardiomyocytes.

Stahlhut M, Petersen JS, Hennan JK, Ramirez MT.

Cell Commun Adhes. 2006 Jan-Apr;13(1-2):21-7.

PMID:
16613777
39.

Rotigaptide (ZP123) reverts established atrial conduction velocity slowing.

Haugan K, Kjølbye AL, Hennan JK, Petersen JS.

Cell Commun Adhes. 2005 Jul-Dec;12(5-6):271-8.

PMID:
16531322
40.

Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways.

Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, Petersen JS, Nielsen JH, Møldrup A.

J Endocrinol. 2006 Mar;188(3):481-92.

PMID:
16522728
41.

Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction.

Haugan K, Marcussen N, Kjølbye AL, Nielsen MS, Hennan JK, Petersen JS.

J Cardiovasc Pharmacol. 2006 Feb;47(2):236-42.

PMID:
16495761
42.

Intrarenal octreotide treatment prevents sodium retention in liver cirrhotic rats: evidence for direct effects within the thick ascending limb of Henle's loop.

Jonassen TE, Christensen S, Marcussen N, Petersen JS.

Am J Physiol Renal Physiol. 2006 Sep;291(3):F537-45. Epub 2006 Jan 17.

43.
44.

The antiarrhythmic peptide analog rotigaptide (ZP123) stimulates gap junction intercellular communication in human osteoblasts and prevents decrease in femoral trabecular bone strength in ovariectomized rats.

Jørgensen NR, Teilmann SC, Henriksen Z, Meier E, Hansen SS, Jensen JE, Sørensen OH, Petersen JS.

Endocrinology. 2005 Nov;146(11):4745-54. Epub 2005 Aug 18.

PMID:
16109789
45.

The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress.

Haugan K, Olsen KB, Hartvig L, Petersen JS, Holstein-Rathlou NH, Hennan JK, Nielsen MS.

J Cardiovasc Electrophysiol. 2005 May;16(5):537-45.

PMID:
15877626
46.

Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity.

Kapusta DR, Thorkildsen C, Kenigs VA, Meier E, Vinge MM, Quist C, Petersen JS.

J Pharmacol Exp Ther. 2005 Aug;314(2):652-60. Epub 2005 Apr 26.

PMID:
15855355
47.

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.

Bregenholt S, Møldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, Knudsen LB, Petersen JS.

Biochem Biophys Res Commun. 2005 May 6;330(2):577-84.

PMID:
15796922
48.
49.

Atrial fibrillation in rats induced by rapid transesophageal atrial pacing during brief episodes of asphyxia: a new in vivo model.

Haugan K, Lam HR, Knudsen CB, Petersen JS.

J Cardiovasc Pharmacol. 2004 Jul;44(1):125-35.

PMID:
15175567
50.

Opioid receptor-like 1 stimulation in the collecting duct induces aquaresis through vasopressin-independent aquaporin-2 downregulation.

Hadrup N, Petersen JS, Praetorius J, Meier E, Graebe M, Brønd L, Staahltoft D, Nielsen S, Christensen S, Kapusta DR, Jonassen TE.

Am J Physiol Renal Physiol. 2004 Jul;287(1):F160-8. Epub 2004 Mar 9.

Supplemental Content

Loading ...
Support Center